BRPI1011776A2 - tratamento de distúrbio pervasivos do desenvolvimento com tocotrienóis ou extratos enriquecidos com trienóis - Google Patents

tratamento de distúrbio pervasivos do desenvolvimento com tocotrienóis ou extratos enriquecidos com trienóis

Info

Publication number
BRPI1011776A2
BRPI1011776A2 BRPI1011776A BRPI1011776A BRPI1011776A2 BR PI1011776 A2 BRPI1011776 A2 BR PI1011776A2 BR PI1011776 A BRPI1011776 A BR PI1011776A BR PI1011776 A BRPI1011776 A BR PI1011776A BR PI1011776 A2 BRPI1011776 A2 BR PI1011776A2
Authority
BR
Brazil
Prior art keywords
trienol
tocotrienols
treatment
developmental disorder
pervasive developmental
Prior art date
Application number
BRPI1011776A
Other languages
English (en)
Portuguese (pt)
Inventor
M Miller Guy
Original Assignee
Ampere Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampere Life Sciences Inc filed Critical Ampere Life Sciences Inc
Publication of BRPI1011776A2 publication Critical patent/BRPI1011776A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI1011776A 2009-06-25 2010-02-25 tratamento de distúrbio pervasivos do desenvolvimento com tocotrienóis ou extratos enriquecidos com trienóis BRPI1011776A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26962709P 2009-06-25 2009-06-25
PCT/US2010/025447 WO2010151348A1 (en) 2009-06-25 2010-02-25 Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts

Publications (1)

Publication Number Publication Date
BRPI1011776A2 true BRPI1011776A2 (pt) 2018-03-13

Family

ID=43386829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011776A BRPI1011776A2 (pt) 2009-06-25 2010-02-25 tratamento de distúrbio pervasivos do desenvolvimento com tocotrienóis ou extratos enriquecidos com trienóis

Country Status (8)

Country Link
US (1) US20120122969A1 (cg-RX-API-DMAC10.html)
EP (2) EP2445519A4 (cg-RX-API-DMAC10.html)
JP (1) JP2012531411A (cg-RX-API-DMAC10.html)
BR (1) BRPI1011776A2 (cg-RX-API-DMAC10.html)
CA (1) CA2765771A1 (cg-RX-API-DMAC10.html)
EA (1) EA201200054A1 (cg-RX-API-DMAC10.html)
MX (1) MX2011013558A (cg-RX-API-DMAC10.html)
WO (1) WO2010151348A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EA035619B1 (ru) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) * 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
NO2470168T3 (cg-RX-API-DMAC10.html) * 2009-08-26 2018-06-30
CA2842486C (en) 2011-07-19 2022-09-06 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
KR20150082109A (ko) 2012-11-13 2015-07-15 고다겐 파마슈티컬스 피티와이 엘티디 토코트리에놀의 경점막 전달
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
CN105744835A (zh) * 2013-07-22 2016-07-06 俄亥俄州国家创新基金会 用于减少热潮红发生的方法
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CA3136303A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for childhood risk of autism spectrum disorder
MY196888A (en) * 2019-11-19 2023-05-08 Hovid Berhad A composition for managing cadasil
EP3981397A1 (en) * 2020-10-08 2022-04-13 Global Scientific Tocotrienols derivates, methods and uses thereof
EP4366700A1 (en) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
AU618791B2 (en) 1988-03-16 1992-01-09 Bioindustry Development Centre Production of high concentration tocopherols and tocotrienols from palm oil by-product
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
EP0543417A1 (en) 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US20030134028A1 (en) * 1995-06-01 2003-07-17 Lipton, Division Of Conopco, Inc. Fat based food products
EP1051412B1 (en) 1998-01-29 2003-09-24 Eastman Chemical Company Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6187811B1 (en) * 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols
US6562372B1 (en) 1998-11-06 2003-05-13 Fuji Chemical Industry Co., Ltd. Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US20030206972A1 (en) * 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US7217133B2 (en) * 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
AT414082B (de) * 2002-05-03 2006-09-15 Vis Vitalis Lizenz & Handels Verfahren zur herstellung von tocotrienol-angereicherten präparationen
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
MXPA06009529A (es) 2004-02-23 2007-04-10 Texas A & M Univ Sys Composiciones antioxidantes y metodos para el uso de las mismas.
ES2732293T3 (es) * 2007-02-22 2019-11-21 Childrens Hospital & Res Center At Oakland Formulaciones de ácidos grasos y métodos para el uso de las mismas
KR101481197B1 (ko) 2007-05-24 2015-01-09 로더스 크로클란 비.브이. 토코페롤 및 토코트리에놀을 함유하는 조성물의 제조방법

Also Published As

Publication number Publication date
JP2012531411A (ja) 2012-12-10
EP2445519A1 (en) 2012-05-02
US20120122969A1 (en) 2012-05-17
EA201200054A1 (ru) 2012-05-30
CA2765771A1 (en) 2010-12-29
MX2011013558A (es) 2012-04-30
WO2010151348A1 (en) 2010-12-29
EP2445519A4 (en) 2012-12-26
EP2609921A1 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
EP2445519A4 (en) TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS USING TOCOTRIENOLS OR TOCOTRIENOLS ENRICHED EXTRACTS
FIC20180025I1 (fi) Bentsovindiflupyyrin ja protiokonatsolin yhdistelmä
PT2640375T (pt) Método de tratamento da nefropatia induzida por contraste
EP2382734A4 (en) VERIFICATION OF SOFTWARE APPLICATIONS
EP2936482A4 (en) IDENTIFICATION OF PERSONAL INFORMATION
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
EP2488146A4 (en) DRUGS LABELING
EP2377680A4 (en) NANO FIBER FILM
PT2414890T (pt) Fabricação de dispositivos electrocrómicos de baixa defetividade
EP2265283A4 (en) Auristatin-DRUG-LINKER CONJUGATES
BRPI0921116A2 (pt) Aperfeiçoamento de sensação bucal de bebidas
LT3827815T (lt) Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
HRP20180972T1 (hr) Kombinacija fenoksibenzamina i polimiksina e za liječenje mikrobnih infekcija
BRPI0820928A2 (pt) Fabricação de elementos com baixa fricção
EP2555765A4 (en) TREATMENT OF LOUIS BAR SYNDROME
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
BR112012000568A2 (pt) tratamento da esclerose múltipla com laquinimod
IL219715A (en) Sewage treatment apparatus
BR112013006785A2 (pt) conjunto de cateter com meio de seurança aperfeiçoado
EP2531438A4 (en) TELESCOPIC INPUT AND REMOVABLE POWER UNIT
BRPI0920136A2 (pt) determinação de sistema óptico de acordo com critérios avançados
BRPI0923956A2 (pt) sistema de cooperação meio-ambiental e troca de benefícios vitais
BR112012009704A2 (pt) dispositivo de iluminação com funcionalidade de despertar e / ou dormir
EP2283670A4 (en) SAFETY MESSAGE PROCESSING

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]